Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Biomedical Engineering

Background:

• Postoperative glioma recurrence remains a significant clinical challenge despite advances in immunotherapy.
• Current immunotherapies show limited efficacy in preventing tumor relapse after surgical resection.
• There is a critical need for novel strategies to target residual tumor cells and enhance antitumor immunity.

Purpose of the Study:

• To develop and evaluate a neoantigen-targeting peptide nanoshield for preventing postoperative glioma recurrence.
• To assess the nanoshield's ability to synergize with glioma resection for complete tumor elimination.
• To investigate the immunogenicity and therapeutic efficacy of the nanovaccine in preclinical glioma models.

Main Methods:

• Constructed a nanoshield using a multicationic protein (MCP) scaffold assembled with mutated isocitrate dehydrogenase 1 (muIDH1) neoantigen.
• Investigated lysosome-escaping delivery and inflammasome-mediated immune activation for CD8+ T cell generation.
• Evaluated nanoshield immunogenicity, in vivo retention, and therapeutic effects in prophylactic and therapeutic glioma models.
• Combined the nanovaccine with anti-programmed death-1 (aPD-1) therapy to assess synergistic effects on recurrence-free survival.

Main Results:

• The nanoshield demonstrated superior and durable immunogenicity, with a 3-fold increase in CD8+ T cells and a 6-fold higher in vivo retention compared to free peptides.
• Significant reduction in tumor size was observed in both prophylactic and therapeutic glioma models.
• Combining the nanovaccine with aPD-1 therapy resulted in over 40% improvement in postoperative recurrence-free survival.
• The strategy induced potent polyfunctional CD8+ T cell responses and robust antitumor immunity.

Conclusions:

• The neoantigen-targeting peptide nanoshield is a promising immunotherapeutic strategy for eliminating residual glioma cells and preventing postoperative recurrence.
• This nanovaccine platform effectively delivers neoantigens, activates the immune system, and generates durable antitumor immunity.
• The synergistic combination with aPD-1 therapy offers significant potential for improving clinical outcomes in glioma patients.